Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

Clinical Endocrinology

Volumn 71, Issue 2, 2009, Pages 237-245

  Colao, Annamaria ^a   Auriemma, Renata S ^a   Rebora, Alberto ^b   Galdiero, Mariano ^a   Resmini, Eugenia ^b   Minuto, Francesco ^b   Lombardi, Gaetano ^a   Pivonello, Rosario ^a   Ferone, Diego ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG FORMULATION; FEMALE; GALLSTONE; HORMONE RELEASE; HUMAN; HYPERHIDROSIS; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALE; MICROADENOMA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 67650317928     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03503.x     Document Type: Article

References (31)

1. Molitch, M.E. (2008) Lanreotide Autogel in the management of acromegaly. Drugs, 68, 724.
2. Croxtall, J.D. Scott, L.J. (2008) Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs, 68, 711 723.
3. Antonijoan, R.M., Barbanoj, M.J., Cordero, J.A. et al. (2004) Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology, 56, 471 476. (Pubitemid 38455612)
4. Caron, P., Beckers, A., Cullen, D.R. et al. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104. (Pubitemid 34084677)
5. Lucas, T., Astorga, R. Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly (2006) Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clinical Endocrinology, 65, 320 326. (Pubitemid 44244921)
6. Murray, R.D. Melmed, S. (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism, 93, 2957 2968.
7. Colao, A., Martino, E., Cappabianca, P. et al. (2006) First-line therapy of acromegaly: a statement of the ALICE (Acromegaly Primary Medical Treatment Learning and Improvement with Continuous Medical Education) Study Group. Journal of Endocrinological Investigation, 29, 1017 1020. (Pubitemid 46344238)
8. Bevan, J.S. (2005) The antitumoural effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1856 1863. (Pubitemid 40464061)
9. Melmed, S., Sternberg, R., Cook, D. et al. (2005) A critical analysis of pituitary tumour shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4405 4410. (Pubitemid 41058228)
10. Colao, A., Pivonello, R., Auriemma, R.S. et al. (2006) Predictors of tumour shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. Journal of Clinical Endocrinology and Metabolism, 91, 2112 2118. (Pubitemid 43854991)
11. Giustina, A., Barkan, A., Casanueva, F.F. et al. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529. (Pubitemid 32273628)
12. Colao, A., Ferone, D., Marzullo, P. et al. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumour mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779 2786. (Pubitemid 32545739)
13. Caron, P., Cogne, M., Raingeard, I. et al. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clinical Endocrinology, 64, 209 214.
14. Ashwell, S.G., Bevan, J.S., Edwards, O.M. et al. (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473 480. (Pubitemid 38584697)
15. Alexopoulou, O., Abrams, P., Verhelst, J. et al. (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317 324. (Pubitemid 39307318)
16. Van Thiel, S.W., Romijn, J.A., Biermasz, N.R. et al. (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489 495. (Pubitemid 38584699)
17. Ronchi, C.L., Boschetti, M., Degli Uberti, E.C. et al. (2007) Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide LAR: an open, multicenter longitudinal study. Clinical Endocrinology, 67, 512 519. (Pubitemid 47416307)
18. Andries, M., Glintborg, D., Kvistborg, A. et al. (2008) A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-1 in patients with acromegaly. Clinical Endocrinology, 68, 473 480. (Pubitemid 351257869)
19. Chanson, P., Borson-Chazot, F., Kuhn, J.M. et al. (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clinical Endocrinology, 69, 299 305. (Pubitemid 352009031)
20. Lombardi, G., Minuto, F., Tamburano, G. et al. (2008) Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogues naive patients with acromegaly. Journal of Endocrinological Investigation, in press.
21. Lundin, P., Engström, B.E., Karlsson, F.A. et al. (1997) Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. American Journal of Neuroradiology, 18, 765 772. (Pubitemid 27175981)
22. Bevan, J.S., Atkin, S.L., Atkinson, A.B. et al. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumour size. Journal of Clinical Endocrinology and Metabolism, 87, 4554 4563.
23. Amato, G., Mazziotti, G., Rotondi, M. et al. (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology, 56, 65 71. (Pubitemid 34107323)
24. Colao, A., Pivonello, R., Rosato, F. et al. (2006) First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clinical Endocrinology, 64, 342 351.
25. Jallad, R.S., Musolino, N.R., Salgado, L.R. et al. (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clinical Endocrinology, 63, 168 175. (Pubitemid 41097985)
26. Mercado, M., Borges, F., Bouterfa, H. et al. (2007) A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology, 66, 859 868. (Pubitemid 47024274)
27. Ronchi, C.L., Rizzo, E., Lania, A.G. et al. (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. European Journal of Endocrinology, 158, 19 25. (Pubitemid 351211036)
28. Besser, G.M., Burman, P. Daly, A.F. (2005) Predictors and rates of treatment-resistant tumour growth in acromegaly. European Journal of Endocrinology, 153, 187 193. (Pubitemid 41167474)
29. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013 3018. (Pubitemid 34816336)
30. Melmed, S., Casanueva, F.F., Cavagnini, F. et al. (2002) Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism, 87, 4054 4058.
31. Bevan, J.S., Newell-Price, J., Wass, J.A. et al. (2008) Home administration of lanreotide Autogel (R) by patients with acromegaly, or their partners, is safe and effective. Clinical Endocrinology, 68, 343 349. (Pubitemid 351257850)